Amygephar SRL
Amygephar reported total assets of 717,127 € at the end of the 2025 financial year (annual accounts filed with the NBB on 19 May 2026).
The score of Amygephar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +182 % Total assets +170 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Amygephar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 18,767 € | ||||
| Equity | 691,257 € | ||||
| Cash | 24,433 € | ||||
| EBITDA | 10,034 € | ||||
| Total assets | 717,127 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 May 2026
- Year ended 31 Dec 2024filed on 19 Jun 2025
- Year ended 31 Dec 2023filed on 12 Jul 2024
- Year ended 31 Dec 2022filed on 20 Apr 2023
- Year ended 31 Dec 2021filed on 14 Jun 2022
Amygephar's financial analysis
- Solvency96.4%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Amygephar
Amygephar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0462.964.568
- VAT number
- BE0462964568
- Peppol
- Registered · 0208:0462964568 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Mar 1998
- Registered office
- 4122 Neupré
- Latest accounts
- 2025 · filed on 19 May 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Amygephar (SRL) has been based in Neupré since 1998, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 18,767 € and equity of 691,257 €; its revenue is not published. Its solvency stands at 96.4%, above the median of its sector (41.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Amygephar
Companies in the same business, of comparable size and area, outside its group.
- Delvaux Holding Business and other management consultancy activities Herstal · balance sheet €1.10m
- T-Oline Business and other management consultancy activities Ferrières · balance sheet 987,312 €
- Mathis Pharma Business and other management consultancy activities Bruges · balance sheet €1.06m
- Gelaphar Retail sale of pharmaceutical products Voeren · balance sheet 774,089 €
- Teirlinck Retail sale of pharmaceutical products Londerzeel · balance sheet 694,347 €
- Pharmacie Overlo Retail sale of pharmaceutical products Silly · balance sheet 754,243 €
- J&L Pharma Retail sale of pharmaceutical products Antwerp · balance sheet 664,453 €
- Lotte Scheldeman Retail sale of pharmaceutical products Bornem · balance sheet 742,475 €
Frequently asked questions about Amygephar
What is the revenue of Amygephar?
Amygephar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Amygephar?
In Belgium, the VAT number is the company number prefixed with BE: BE0462964568 for Amygephar, if the company is VAT-registered. Its company number (CBE) is 0462.964.568.
Where is the registered office of Amygephar?
According to the CBE register, the registered office of Amygephar is in 4122 Neupré.
What is the equity of Amygephar?
At the close of the 2025 financial year, the equity of Amygephar amounts to 691,257 €, a solvency of 96.4% of total assets.
Who manages Amygephar?
The register lists 2 active mandates at Amygephar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Amygephar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →